Aldeyra Therapeutics, Inc. Class Action Lawsuit - ALDX
Case Summary
Investors who suffered a loss and would like to learn more, click here to contact us.
The Aldeyra Therapeutics class action lawsuit seeks to represent purchasers or acquirers of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) publicly traded securities between November 3, 2023 and March 16, 2026, inclusive (the “Class Period”). Captioned Kirby v. Aldeyra Therapeutics, Inc., No. 26-cv-11510 (D. Mass.), the Aldeyra Therapeutics class action lawsuit charges Aldeyra Therapeutics and certain of Aldeyra Therapeutics’ top current and former executive officers with violations of the Securities Exchange Act of 1934.
If you suffered substantial losses and wish to serve as lead plaintiff of the Aldeyra Therapeutics class action lawsuit, please provide your information in the form on this page. You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/449-4900 or via e-mail at info@rgrdlaw.com. Lead plaintiff motions for the Aldeyra Therapeutics class action lawsuit must be filed with the court no later than May 29, 2026.
CASE ALLEGATIONS: Aldeyra Therapeutics is a biotechnology company that discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis.
The Aldeyra Therapeutics class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) the results of the reproxalap clinical trials were inconsistent; and (ii) the inconsistency of the results rendered any positive findings from these trials unreliable and not meaningful.
The Aldeyra Therapeutics class action lawsuit further alleges that March 17, 2026, Aldeyra Therapeutics disclosed that it received a Complete Response Letter which stated that the “‘inconsistency of study results raises serious concerns about the reliability and meaningfulness of the positive findings’” and that “‘the totality of evidence from the completed clinical trials does not support the effectiveness of the product.’” On this news, the price of Aldeyra Therapeutics stock fell more than 70%, according to the complaint.
THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Aldeyra Therapeutics publicly traded securities during the Class Period to seek appointment as lead plaintiff in the Aldeyra Therapeutics class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Aldeyra Therapeutics investor class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Aldeyra Therapeutics shareholder class action lawsuit. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Aldeyra Therapeutics class action lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs’ firms in the world, and the Firm’s attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.